A5011625621- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Cancer Treatment and Pharmacology
- Multiple Myeloma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Retinoids in leukemia and cellular processes
- Radiopharmaceutical Chemistry and Applications
- Platelet Disorders and Treatments
- Cutaneous lymphoproliferative disorders research
- Glycosylation and Glycoproteins Research
- Blood groups and transfusion
- Colorectal Cancer Surgical Treatments
- Liver physiology and pathology
- Biosimilars and Bioanalytical Methods
- Immune cells in cancer
- Research on Leishmaniasis Studies
- PI3K/AKT/mTOR signaling in cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Phagocytosis and Immune Regulation
Molecular Partners (Switzerland)
2020-2024
Ablynx (Belgium)
2016-2021
Argenx (Belgium)
2021
Fondazione IRCCS Istituto Neurologico Carlo Besta
2019
University Health Network
2019
Inserm
2016
Université de Caen Normandie
2016
Centre Hospitalier Universitaire de Caen Normandie
2016
Centre Hospitalier Universitaire de Grenoble
2016
Bristol-Myers Squibb (Switzerland)
2014
BACKGROUND. Intravenous Ig (IVIg), plasma exchange, and immunoadsorption are frequently used in the management of severe autoimmune diseases mediated by pathogenic IgG autoantibodies. These approaches modulating levels can, however, be associated with some adverse reactions a substantial burden to patients. Targeting neonatal Fc receptor (FcRn) presents an innovative potentially more effective, safer, convenient alternative for clearing IgGs.
<h3>Objective</h3> To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 fragment, in patients with generalized myasthenia gravis (gMG) a history anti-acetylcholine (AChR) autoantibodies, who were on stable standard-of-care (MG) treatment. <h3>Methods</h3> A phase 2, exploratory, randomized, double-blind, placebo-controlled, 15-center study is described. Eligible randomly assigned (1:1) to receive 4 doses over 3-week period...
Abstract Primary immune thrombocytopenia (ITP) is an acquired autoimmune bleeding disorder, characterized by a low platelet count (<100 × 10 9 /L) in the absence of other causes associated with thrombocytopenia. In most patients, IgG autoantibodies directed against receptors can be detected. They accelerate clearance and destruction, inhibit production, impair function, resulting increased risk impaired quality life. Efgartigimod human IgG1 antibody Fc‐fragment, natural ligand neonatal Fc...
Purpose This analysis of the FIRST trial in patients with newly diagnosed multiple myeloma (MM) ineligible for stem-cell transplantation examined updated outcomes and impact patient age. Patients Methods untreated symptomatic MM were randomly assigned at a one-to-one-to-one ratio to lenalidomide plus low-dose dexamethasone until disease progression (Rd continuous), Rd 72 weeks (18 cycles; Rd18), or melphalan, prednisone, thalidomide (MPT; weeks), stratified by age (≤ 75 v > years), stage...
Purpose: The purpose of this study was to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor efficacy ARGX-110, a glyco-engineered monoclonal antibody, targeting CD70, in patients with CD70 expressing advanced malignancies.Experimental Design: Dose escalation sequential 3+3 design performed five steps at the 0.1, 1, 2, 5, 10 mg/kg dose levels (N = 26). ARGX-110 administered intravenously every 3 weeks until progression or intolerable toxicity. Dose-limiting...
The histopathologic features of acute radiation-induced colitis in humans have been described occasional, >20-year-old studies, but they not analyzed detail. We characterize such findings 34 patients with rectal cancer who underwent surgery a few days after preoperative irradiation 25 Gy given over 5–7 days, and we compare the results to detected 18 treated by conventional protocol consisting 45 during 5 weeks followed time interval at least 3 weeks. Short-term therapy generally induced...
Abstract The prognosis of patients with acute myeloid leukemia (AML) is limited, especially for elderly or unfit not eligible hematopoietic stem cell (HSC) transplantation. disease driven by leukemic cells (LSCs), which are characterized clonal heterogeneity and resistance to conventional therapy. These therefore believed be a major cause progression relapse. We designed MP0533, multispecific CD3-engaging ankyrin repeat protein (DARPin) that can simultaneously bind three antigens on AML...
Renal impairment is associated with poor prognosis in myeloma. This analysis of the pivotal phase 3 FIRST trial examined impact renally adapted dosing lenalidomide and dexamethasone on outcomes patients different degrees renal impairment. Transplant-ineligible not requiring dialysis were randomized 1:1:1 to receive continuous until disease progression (n=535) or for 18 cycles (72 weeks; n=541), melphalan, prednisone, thalidomide 12 n=547). Follow-up ongoing. Patients grouped by baseline...
PURPOSE A first-in-human study was performed with MP0250, a DARPin drug candidate. MP0250 specifically inhibits both vascular endothelial growth factor (VEGF) and hepatocyte (HGF) the aim of disrupting tumor microenvironment. PATIENTS AND METHODS multicenter, open-label, repeated-dose, phase I conducted to assess safety, tolerability, pharmacokinetics in 45 patients advanced solid tumors. In dose-escalation part, 24 received as 3-hour infusion once every 2 weeks at five different dose levels...
Abstract The death-associated protein kinase 2 (DAPK2) belongs to a family of Ca2+/calmodulin-regulated serine/threonine kinases involved in apoptosis. During investigation candidate genes operative granulopoiesis, we identified DAPK2 as highly expressed. Subsequent investigations demonstrated particularly high expression normal granulocytes compared with monocytes/macrophages and CD34+ progenitor cells. Moreover, significantly increased mRNA levels were seen when cord blood cells induced...
Background The clinical benefit of cusatuzumab, a CD70‐directed monoclonal antibody with enhanced effector functions, was investigated in patients relapsed/refractory (R/R) cutaneous T‐cell lymphoma (CTCL). Methods In this cohort expansion the ARGX‐110‐1201 study, 27 R/R CTCL received cusatuzumab at 1 (n = 11) or 5 mg/kg 16) once every 3 weeks to investigate its safety, dose, and exploratory efficacy. pharmacokinetics, immunogenicity, CD70 expression, CD70/CD27 biology were also assessed....
Summary. One fifth of B‐cell chronic lymphocytic leukaemia (B‐CLL) patients exhibit loss heterozygosity (LOH) at 10q23.3, the site tumour suppressor PTEN. Microsatellite markers mapped complete LOH to 10q23.3 in 2/41 B‐CLL (5%) and allelic imbalances 6/41 (15%). No PTEN gene mutations were found. protein expression was not detected 11 (28%), reduced eight (20%). or fairly frequent B‐CLL, but did encompass gene. Nevertheless, may be absent with a normal genotype, suggesting role this...
B-cell chronic lymphocytic leukemia is a heterogenous disease with disturbed apoptosis in which the precise molecular defects leading to this pathogenesis are still unclear. The p73 gene (a p53 homologue) encodes 2 proteins opposing functions. TAp73 induces cell cycle arrest and apoptosis, whilst oncogenic deltaNp73 inhibits both induced apoptosis. Microsatellite analysis was performed investigate locus B-CLL. Moreover, we investigated expression of variant by measuring mRNA transcripts 51...
MP0250 is a designed ankyrin repeat protein that specifically inhibits both vascular endothelial growth factor A (VEGF-A) and hepatocyte (HGF), aiming at potentiating cancer therapy by disrupting the tumour microenvironment. Encouraging results from phase 1 trial of in patients with solid tumours prompted further investigation multiple myeloma (MM) as targets are reported to be drivers MM pathogenesis. In this open-label, single-arm 1b/2 study (NCT03136653) proteasome inhibitor- and/or...
Summary Microarray gene expression profiles of fresh clinical samples chronic myeloid leukaemia in phase, acute promyelocytic and monocytic were compared with from cell lines representing the corresponding types (K562, NB4, HL60). In a hierarchical clustering analysis, all clustered separately lines, regardless leukaemic subtype. Gene ontology analysis showed that chiefly overexpressed genes related to macromolecular metabolism, whereas immune response abundantly expressed. These findings...
This phase II trial investigated rituximab and cladribine in chronic lymphocytic leukemia. Four induction cycles, comprising (0.1 mg/kg/day days 1-5, cycles 1-4) (375 mg/m(2) day 1, 2-4), were given every 28 days. Stem cell mobilization (rituximab 375 1 8; cyclophosphamide 4 g/m(2) 2; granulocyte colony-stimulating factor 10 microg/kg/day, from 4) was performed responders. Of 42 patients, nine achieved complete remission (CR), 15 very good partial remission, two nodular (overall response...